Stem cell types | POF model | The transplantation of stem cells from adult tissues | Stem cell from references | ||||
---|---|---|---|---|---|---|---|
Animal | Drug | Stem Cells | Treatment | Main effects of stem cell on POF | Mechanism | ||
BMSCs | Rats (5 weeks) | CTX (1st, 50 mg/kg, 8 mg/kg for 14 days) | BMSCs (1 × 106 cells) in 100μL PBS for 2w | iv | Increase E2 and AMH, decrease FSH level; Recover the estrous cycle; Increase the number of basal and sinus follicles | BMSC-derived exosome Mir-144-5p has a protective effect on the apoptosis of CTX-damaged OGCs | [23] |
Rats (3 weeks) | 3.2 Gy radiotherapy (0.48 Gy/min) | BMSCs (2 × 106 cells) in 150μL PBS | iv | Enhances ovarian follicles; Increases serum estradiol- and follicle-stimulating hormone levels; Restores fertility | Upregulates Wnt/β-catenin and Hippo signaling pathways | [59] | |
Exosome from BMSCs | Mice (6–7 weeks) | CIS (5 mg/kg) | BMSCs-Exos (125 μg dissolved in 100 μL PBS | iv | Inhibit OGCs apoptosis; Increase E2; | delivering miR-644-5p to granulosa cells to regulate p53 expression of cells | [60] |
Rats (5 weeks) | CTX (1st, 50 mg/kg, 8 mg/kg for 14 days ) | BMSCs-Exos (150 μg dissolved in 100 μL PBS; every other day for 2 weeks) | iv | Decrease FSH and LH, increase AMH, E2; Inhibit OGCs apoptosis; | Exosomes miR-144-5p inactivated the PI3K/AKT pathway by suppressing PTEN targeting | [23] | |
ADMSCs | Rats | CTX (120 mg/kg) | ADMSCs (1 × 106 cells, passages 3–4) | Ip | Increase the number of primordial follicles and decrease the number of atretic follicles; Increase AMH level; Inhibit the apoptosis of follicle | Regulate the expression of Connexin43 and pAnnexin1 | [61] |
Exosome from ADMSCs | Mice (7–8 weeks) | CTX (120 mg/kg for 2 weeks) | hADSC-Exos (1 × 106 cells, cocultured with hGCs) | Ip | Attenuate ovary damage; Increase the number of follicles; Enhanced the E2 and AMH levels and decreased the FSH levels; Inhibit OGCs apoptosis | Increase expression of SMAD2, SMAD3, and SMAD5 in vivo and in vitro | [62] |
HuMenSCs | Mice (7–8 weeks) | CIS (2 mg/kg for 7 days ) | HuMenSCs (2 × 106/mL) in 200 μL PBS | iv | Increase body and ovary weight; Increase the number of follicles; Reduce OGCs apoptosis; repair ovarian injury, Stimulate regeneration, and improve ovarian function | Protects damaged ovaries by secreting FGF2 | [63] |
Rats (8Â weeks) | BF (36Â mg/kg) | HuMenSCs (Passages 3) | iv | Improve follicle development; Promote AMH and E2 secretion | NO Report | [64] | |
Rats (6–8 weeks) | BF (36 mg/kg) | HuMenSCs (1 × 106 cells per 200 μL) in 1 mL PBS | iv | Increased body and ovary weight; Increase the number of follicles; Reduce OGCs apoptosis | NO Report | [58] | |
Mice (18–19 g) | CTX (120 mg/kg) + BF (30 mg/kg) | hEnSCs (2 × 106 cells, passages 5) in 20 μL PBS | Orthotopically inject | Increased body weight; Improved estrous cycles; Restored fertility | Reduce chemotherapy-induced depletion of the germline stem cell pool | [57] |